OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Diabetes Investigation is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Japanese Clinical Practice Guideline for Diabetes 2019	156
Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy	139
Sodium–glucose cotransporters: Functional properties and pharmaceutical potential	67
Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017	65
Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study	56
Current concepts in the management of diabetic polyneuropathy	55
Retrospective nationwide study on the trends in first‐line antidiabetic medication for patients with type 2 diabetes in Japan	46
Insulin resistance surrogates predict hypertension plus hyperuricemia	46
Impaired nicotinamide adenine dinucleotide (NAD⁺) metabolism in diabetes and diabetic tissues: Implications for nicotinamide‐related compound treatment	44
Dissecting the interaction between COVID‐19 and diabetes mellitus	43
The PKM2 activator TEPP‐46 suppresses kidney fibrosis via inhibition of the EMT program and aberrant glycolysis associated with suppression of HIF‐1α accumulation	42
Whole transcriptome expression profiles in placenta samples from women with gestational diabetes mellitus	41
Hypoglycemia unawareness and autonomic dysfunction in diabetes: Lessons learned and roles of diabetes technologies	41
Association between the triglyceride–glucose index and diabetic nephropathy in patients with type 2 diabetes: A cross‐sectional study	36
Association between tear and blood glucose concentrations: Random intercept model adjusted with confounders in tear samples negative for occult blood	35
Intake of sucrose affects gut dysbiosis in patients with type 2 diabetes	34
Role of skeletal muscle lipids in the pathogenesis of insulin resistance of obesity and type 2 diabetes	33
High prevalence and clinical impact of dynapenia and sarcopenia in Japanese patients with type 1 and type 2 diabetes: Findings from the Impact of Diabetes Mellitus on Dynapenia study	33
Type 1 diabetes mellitus following COVID‐19 RNA‐based vaccine	32
Loss of metabolic flexibility as a result of overexpression of pyruvate dehydrogenase kinases in muscle, liver and the immune system: Therapeutic targets in metabolic diseases	30
Relationships between gut microbiota, plasma glucose and gestational diabetes mellitus	29
VX‐765 ameliorates renal injury and fibrosis in diabetes by regulating caspase‐1‐mediated pyroptosis and inflammation	29
Association of time in range, as assessed by continuous glucose monitoring, with painful diabetic polyneuropathy	28
Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone	27
Non‐alcoholic fatty liver disease and type 2 diabetes: An update	27

Relationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition	27
β‐Cell failure in diabetes: Common susceptibility and mechanisms shared between type 1 and type 2 diabetes	26
Identification of two novel subgroups in patients with diabetes mellitus and their association with clinical outcomes: A two‐step cluster analysis	26